N
GSK icon

Nuveen’s GSK GSK Stock Holding History

Nuveen’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Sell
23,472
-1,029
-4% -$55.8K ﹤0.01% 2468
2025
Q4 		$1.2M Sell
24,501
-1,047
-4% -$48.8K ﹤0.01% 2530
2025
Q3 		$1.1M Sell
25,548
-467
-2% -$18.2K ﹤0.01% 2575
2025
Q2 		$999K Sell
26,015
-11,569
-31% -$442K ﹤0.01% 2604
2025
Q1 		$1.46M Sell
37,584
-4,709
-11% -$172K ﹤0.01% 2468
2024
Q4 		$1.43M Sell
42,293
-7,310
-15% -$263K ﹤0.01% 2529
2024
Q3 		$2.03M Sell
49,603
-2,825
-5% -$116K ﹤0.01% 2403
2024
Q2 		$2.02M Buy
52,428
+13
+0% +$547 ﹤0.01% 2393
2024
Q1 		$2.25M Buy
52,415
+14,255
+37% +$588K ﹤0.01% 2346
2023
Q4 		$1.41M Buy
38,160
+37,661
+7,547% +$1.35M ﹤0.01% 2575
2023
Q3 		$18.1K Buy
+499
New +$17.7K ﹤0.01% 3177
2022
Q1 		– Sell
-719,314
Closed -$39.7M – 3399
2021
Q4 		$39.7M Sell
719,314
-717,034
-50% -$37.3M 0.01% 805
2021
Q3 		$68.6M Sell
1,436,348
-69,038
-5% -$3.47M 0.02% 560
2021
Q2 		$74.9M Sell
1,505,386
-28,262
-2% -$1.36M 0.02% 581
2021
Q1 		$68.4M Sell
1,533,648
-328,810
-18% -$14.9M 0.02% 589
2020
Q4 		$85.7M Buy
1,862,458
+1,674,527
+891% +$76.9M 0.03% 478
2020
Q3 		$8.84M Sell
187,931
-46,400
-20% -$2.32M ﹤0.01% 1597
2020
Q2 		$11.9M Sell
234,331
-3,099,721
-93% -$159M ﹤0.01% 1363
2020
Q1 		$158M Buy
3,334,052
+624,665
+23% +$33.3M 0.08% 230
2019
Q4 		$159M Buy
2,709,387
+2,536,329
+1,466% +$141M 0.06% 300
2019
Q3 		$9.23M Buy
173,058
+2,974
+2% +$153K ﹤0.01% 1626
2019
Q2 		$8.51M Buy
170,084
+6,606
+4% +$331K ﹤0.01% 1704
2019
Q1 		$8.54M Buy
163,478
+4,796
+3% +$240K 0.05% 437
2018
Q4 		$7.58M Sell
158,682
-1,678
-1% -$82.6K 0.05% 430
2018
Q3 		$8.05M Buy
160,360
+162
+0.1% +$8.23K 0.04% 466
2018
Q2 		$8.07M Buy
160,198
+601
+0.4% +$30.3K 0.05% 432
2018
Q1 		$7.79M Buy
+159,597
New +$7.43M 0.05% 416
2017
Q1 		– Sell
-239,386
Closed -$11.6M – 1413
2016
Q4 		$11.6M Buy
239,386
+63,616
+36% +$3.14M 0.06% 406
2016
Q3 		$9.48M Buy
175,770
+708
+0.4% +$38.8K 0.06% 396
2016
Q2 		$9.48M Sell
175,062
-1,072
-0.6% -$56.5K 0.06% 363
2016
Q1 		$8.93K Sell
176,134
-89,883
-34% -$4.48M 0.05% 356
2015
Q4 		$13.4K Buy
266,017
+73,493
+38% +$3.75M 0.07% 285
2015
Q3 		$9.25K Sell
192,524
-83,634
-30% -$4.35M 0.05% 347
2015
Q2 		$14.4K Sell
276,158
-7,219
-3% -$406K 0.08% 308
2015
Q1 		$16.3M Sell
283,377
-7,645
-3% -$438K 0.09% 298
2014
Q4 		$15.5M Sell
291,022
-9,023
-3% -$505K 0.09% 301
2014
Q3 		$17.2M Sell
300,045
-1,473
-0.5% -$90.3K 0.11% 268
2014
Q2 		$20.2M Buy
301,518
+94
+0% +$6.36K 0.12% 228
2014
Q1 		$20.1M Sell
301,424
-88,578
-23% -$5.99M 0.12% 231
2013
Q4 		$26M Buy
390,002
+5,160
+1% +$335K 0.17% 174
2013
Q3 		$24.1M Sell
384,842
-38,912
-9% -$2.5M 0.16% 178
2013
Q2 		$26.5M Buy
+423,754
New +$26.9M 0.18% 149

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Nuveen's GSK Position: Q1 2026 in Review

Nuveen reduced its GSK (GSK) stake by 4.2% in Q1 2026, selling an estimated $55.8K and leaving 23,472 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Nuveen first reported a position in GSK in Q2 2013 and has held it in 42 quarters since. The position peaked at $159M in Q4 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Nuveen held 23,472 shares of GSK worth $1.3M as of Q1 2026.
  • Nuveen sold 1,029 GSK shares in Q1 2026, an estimated $55.8K.
  • GSK made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2468 holding.
  • Nuveen first reported a position in GSK in Q2 2013 and has held it in 42 quarters since.
  • Nuveen's GSK position peaked at $159M in Q4 2019.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.